Betamethasone butyrate propionate/maxacalcitol

Drug Profile

Betamethasone butyrate propionate/maxacalcitol

Alternative Names: M 8010; M 801801; Marduox; Maxacalcitol/betamethasone butyrate propionate

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Maruho
  • Developer Maruho
  • Class Analgesics; Anti-inflammatories; Antipruritics; Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Small molecules
  • Mechanism of Action Steroid receptor antagonists; Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Plaque psoriasis

Most Recent Events

  • 28 Mar 2016 Registered for Plaque psoriasis in Japan (Topical)
  • 25 May 2015 Preregistration for Plaque psoriasis in Japan (Topical)
  • 25 May 2015 Adverse events data from a phase III trial in Plaque psoriasis released by Chugai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top